Nektar Therapeutics (NKTR, Financial) experienced a significant stock surge, with a rapid increase of 5.38% in its share price, reaching $1.37 per share. The trading volume hit 358,533 shares, showing a turnover rate of 0.19% and a fluctuation of 5.38%.
The recent financial report indicated that Nektar reported a revenue of $23.49 million, a net loss of $52.36 million, and an earnings per share (EPS) of -$0.25. The gross profit stood at $13.75 million, with a price-to-earnings (P/E) ratio of -1.51. Regarding institutional ratings, of the six firms that participated, 17% recommended buying, 67% holding, and 16% selling the stock.
Within the broader biotechnology sector, there was an overall decline of 0.10%. Notable performers in the sector included Nkgen Biotech Inc and Entero Therapeutics Inc., with significant gains, while Aditxt, Inc. and Seelos Therapeutics, Inc. showed marked trading activity with turnover rates of 17,567.70% and 94.70%, respectively. Stocks with notable price fluctuations included Nkgen Biotech Inc and Geovax Labs Inc.
Nektar Therapeutics is a biopharmaceutical company with a focus on oncology, immunology, and virology. Its research and development pipeline includes proprietary drugs and collaborations, targeting cancer through immune system activation, addressing immune system imbalances, and applying selective immunomodulators for viral infections.
